At 10 years, treatment with leuprorelin did not significantly improve OS (89.1% vs 88.9%) or disease-specific survival (98.6% vs 96.5%) compared with observation. The administration of leuprorelin ...

Adherence to American Society of Clinical Oncology (ASCO) language of respect (LoR) guidelines in ASCO Annual Meeting prostate cancer (PCa) abstracts. This is an ASCO Meeting Abstract from the 2024 ...

HONG KONG – Taiwan-U.S. biopharma company Foresee Pharmaceutical Co. Ltd. has out-licensed its core asset FP-001 (leuprorelin depot) for treating prostate cancer to U.K.-based Accord Healthcare in an ...

Hormone blockade therapy, which includes both oral and injectable options, aims to slow or stop the growth of prostate cancer cells by reducing androgen levels. Injectable hormone blockade therapies, ...